-
12
2023
2023.12.27 -
Caliway to Present CBL-514 Phase 2 Study Results for Subcutaneous Fat Reduction at IMCAS 2024
CBL-514 Phase 2 Study Results for local fat reduction demonstrated 85.7% and 76.2% of participants lost at least 150mL and 200mL of abdominal subcutaneous fat in the treated area after receiving CBL-514 treatment(s).
-
12
2023
2023.12.15 -
Caliway Closes Oversubscribed Capital Raise and Secures Over $100M to Advance CBL-514 Pivotal Phase 3 Study in Subcutaneous Fat Reduction
Caliway announced that it has closed an oversubscribed capital raise, securing over $100M by issuing 8 million new shares.
-
10
2023
Caliway's CBL-514 Achieved Better Efficacy than Liposuction, Reducing over 300mL of Subcutaneous Fat on Average in CBL-0202 Study
CBL-0202 Phase 2 study results met all the primary and secondary endpoints.
-
09
2023
Caliway Announces the Completion of Subject Recruitment in the CBL-0201EFP Phase 2-stage 2 Study Evaluating the CBL-514 in Cellulite Treatment
Caliway announced the completion of subject recruitment in the CBL-0201EFP Phase 2-stage 2 study.
-
09
2023
The Positive Topline Results from the CBL-514 Phase 2 Study for Dercum’s Disease Showed 64.5% of Painful Lipomas with Complete Clearance or Dimensions Reduction of more than 50% and Significantly Reduced Pain by 4.7 Points
CBL-0201DD Phase 2 study met the primary and all secondary endpoints.
-
07
2023
Caliway Receives IND approval from the U.S. FDA for the CBL-0205 Phase 2b Study Evaluating CBL-514 in Abdominal Subcutaneous Fat Reduction
Caliway announces that the U.S. FDA has approved the company’s IND application for CBL-514 injection’s CBL-0205 Phase 2b Study.
-
-
06
2023
Caliway Announces Positive Data from CBL-0201EFP Phase 2-Stage 1 Study of CBL-514 in Treating Moderate to Severe Cellulite
The highest dose of CBL-514 treatment demonstrated the best efficacy, 87.5% of thighs achieved at least 1-level improvement in cellulite severity two weeks after CBL-514 treatment.
